Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Zoetis (NYSE: ZTS) received a USDA license for Cytopoint Plus, an injectable antibody treatment for allergic dermatitis in dogs. A single veterinarian-administered injection provides 75 days of allergic itch relief, with repeat administration every 75 days as needed.
Studies supporting approval demonstrated efficacy through Day 75 and a safety profile similar to Cytopoint. Reduced itch scores compared with controls were observed through Day 90 in some dogs. The treatment joins Zoetis’ dermatology portfolio alongside Cytopoint, which provides 4 to 8 weeks of relief, and Apoquel. Cytopoint Plus targets IL-31, a protein involved in sending itch signals.
Zoetis (NYSE:ZTS) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026.
Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will speak at 2 p.m. GMT. A live webcast will be available on the investor website, with a replay available after the event.
Zoetis (NYSE:ZTS) reported third-quarter 2026 revenue of $2.4 billion, down from the prior year, while raising its full-year adjusted earnings guidance. Revenue fell 1% on both reported and organic operational bases, which exclude currency effects and certain acquisitions and divestitures. Net income fell 18% to $591 million, and diluted earnings per share fell 12% to $1.44. Adjusted diluted EPS rose 3% to $1.75.
U.S. revenue declined 6% to $1.2 billion, while International revenue increased 4% to $1.1 billion. Zoetis narrowed its 2026 revenue forecast to $9.220 billion–$9.320 billion and raised adjusted EPS guidance to $6.25–$6.35. It expects organic operational revenue to decline 2%–1%. The company also received FDA approval for Convenia RTU for Dogs and now expects select approvals previously anticipated in 2027 in the fourth quarter of 2026.
Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs to treat susceptible bacterial skin infections in dogs. The approved uses cover secondary superficial pyoderma, abscesses and wounds caused by susceptible strains of Staphylococcus pseudintermedius and Streptococcus canis (Group G). Administered by a veterinary professional, one injection provides up to 14 days of antibiotic treatment. Zoetis expects availability to veterinarians in Q1 2027.
The formulation is bioequivalent to Convenia and delivers the same dose in a smaller volume. In a study of cefovecin, 86% of dogs needed just one injection to resolve their bacterial skin infection. Convenia RTU for Dogs must not be used in cats because of toxicity risk, or in animals with a history of allergic reactions to penicillins or cephalosporins.
Zoetis (ZTS) has appointed Iris Knobloch to its Board of Directors, with the appointment effective December 1, 2026.
Knobloch currently serves on the boards of Deezer, Lazard and Vail Resorts and has been President of the Festival de Cannes since July 2022. She previously held senior executive roles at WarnerMedia. Her appointment will increase the Zoetis board from 12 to 13 members, effective December 1, 2026.
Zoetis (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026 through its board of directors. The dividend will be paid on December 1, 2026, to common stockholders of record as of the close of business on October 30, 2026.
Zoetis (ZTS) announced peer-reviewed laboratory findings showing Simparica Trio protected more dogs from resistant heartworm infection than NexGard Plus.
The study, published in Parasites & Vectors, challenged 24 dogs with the ZoeLA isolate, resistant to the drug class used in heartworm preventives. Dogs received either product or a negative control monthly for six months at labeled dosages. Adult heartworms were found in 2/8 (25%) Simparica Trio-treated dogs versus 6/8 (75%) NexGard Plus-treated dogs. Efficacy versus untreated controls was 99.5% and 98.1%, respectively. Average adult worm counts were 0.2 versus 0.7, with a statistically significant difference (P = 0.0316).
No Simparica Trio-treated dogs had detectable circulating heartworm offspring at study end, versus one NexGard Plus-treated dog. No treatment-related adverse events were recorded in any dog.
Zoetis (ZTS) will host a webcast and conference call on November 5, 2026, at 8:30 a.m. ET to discuss third-quarter 2026 results.
Chief Executive Officer Kristin Peck and Jay Saccaro, the company’s Chief Financial Officer and Chief Operating Officer, will review the results and answer questions from financial analysts.
Zoetis (ZTS) announced that CEO Kristin Peck and EVP, CFO and COO Jay Saccaro will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET.
A live audio webcast and replay will be available via the Zoetis investor relations website.
Zoetis (NYSE:ZTS) received a U.S. FDA Emergency Use Authorization (EUA) for Simparica Trio (sarolaner, moxidectin, pyrantel) to treat infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. The EUA applies only for the duration of the federal emergency declaration and does not constitute full approval for this use.
Simparica Trio remains FDA‑approved for broad parasite protection in dogs, including heartworm, multiple tick species, fleas, roundworms, hookworms and flea‑transmitted tapeworm. Zoetis also highlights Dectomax/Dectomax‑CA1, which hold conditional approval and EUA-based uses against New World screwworm in several livestock species, with specified withdrawal periods and species restrictions.